Altimmune doubles authorized common shares
Altimmune, Inc. reported results from its 2026 Annual Meeting and a key charter change.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Altimmune, Inc. reported results from its 2026 Annual Meeting and a key charter change. Stockholders approved an amendment to increase authorized common shares from 200,000,000 to 400,000,000, giving the company more capacity to issue stock in the future.
As of March 13, 2026, 130,105,177 shares were outstanding and entitled to vote, with 88,270,365 shares represented, a 67.8% quorum. Stockholders elected all director nominees, ratified Ernst & Young LLP as auditor, approved the advisory say-on-pay vote, expanded the 2019 Employee Stock Purchase Plan reserve from 403,500 to 1,108,827 shares, and authorized potential adjournment of the meeting to solicit additional proxies.
8-K Event Classification
3 items: 5.03, 5.07, 9.01
3 items
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Authorized common shares: 400,000,000 shares
Shares outstanding and entitled to vote: 130,105,177 shares
Shares represented at meeting: 88,270,365 shares
+4 more
7 metrics
Authorized common shares
400,000,000 shares
Increased from 200,000,000 via charter amendment
Shares outstanding and entitled to vote
130,105,177 shares
As of March 13, 2026 record date
Shares represented at meeting
88,270,365 shares
67.8% of issued and outstanding entitled to vote
Auditor ratification votes for
84,959,584 shares
Ernst & Young LLP ratified for year ending December 31, 2026
ESPP reserve increase
From 403,500 to 1,108,827 shares
2019 Employee Stock Purchase Plan amendment approved
Amendment to increase authorized shares
63,684,172 for; 24,151,522 against; 434,671 abstain
Proposal to raise authorized common shares to 400,000,000
Adjournment authorization
68,318,332 for; 18,755,920 against; 1,196,113 abstain
Proposal to authorize adjournment to solicit additional proxies
Key Terms
Amended and Restated Certificate of Incorporation, quorum, broker non-votes, say-on-pay, +1 more
5 terms
Amended and Restated Certificate of Incorporation regulatory
"amended its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”)"
A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.
quorum regulatory
"88,270,365 shares of common stock were present or represented by proxy ... representing a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
broker non-votes financial
"39,928,184 For ... 460,516 Abstain ... 35,855,584 Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
say-on-pay financial
"the “say-on-pay” proposal"
A say-on-pay is a shareholder vote that gives investors a chance to approve or disapprove a company’s executive compensation packages, typically held at annual meetings. It matters because the vote signals investor satisfaction with how leaders are paid—like customers rating how well managers are rewarded—and can push boards to change pay plans, reducing governance risk and affecting investor confidence and stock value even though the vote is usually advisory rather than legally binding.
Employee Stock Purchase Plan financial
"amendment to the Company’s 2019 Employee Stock Purchase Plan (the “2019 ESPP”)"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What change was made to Altimmune’s (ALT) 2019 Employee Stock Purchase Plan?
Shareholders approved increasing the 2019 Employee Stock Purchase Plan share reserve from 403,500 to 1,108,827 common shares. This expansion allows more employee participation in share purchases under the plan over time, aligning staff incentives with company performance.
Were all Altimmune (ALT) director nominees elected at the 2026 Annual Meeting?
Yes, all director nominees, including Chairman Jerome Durso and eight other directors, were elected. For example, Durso received 47,577,875 votes for and 4,836,906 withheld, with 35,855,584 broker non-votes recorded on the director election proposals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates